Trial NCT03644550

View at ClinicalTrials.gov 
Org. Study IDs: 180136
Secondary IDs: 18-C-0136

Last trial update was posted on 2021-12-02

MeSH Interventions

LMB-100 Pembrolizumab

MeSH Conditions

Mesothelioma Mesothelioma, Malignant

Other Conditions


Stopping Reasons

Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID